This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2010 by Hospital Universitari Vall d'Hebron Research Institute.
Recruitment status was:  Recruiting
Information provided by:
Hospital Universitari Vall d'Hebron Research Institute Identifier:
First received: February 16, 2007
Last updated: May 26, 2010
Last verified: May 2010

Borderline Personality Disorder (BDP) is a serious mental disorder that affects about 1-2% of the general population, and it is characterized by severe psychosocial impairment and a high mortality rate due to suicide. Currently, the most effective treatments for BPD are psychotherapy (cognitive behavior therapy - CBT -) and pharmacotherapy (often as an important adjunctive role, especially for diminution of symptoms such as affective instability, impulsivity, psychotic-like symptoms and self-destructive behavior). Nevertheless, although several drugs are used in these patients, these drugs induce an improvement of some symptoms but do not cause the remission of BPD. Thus, identification of novel treatments is needed.

The objective of this study is to examine the efficacy of Omacor® ( a mixture of omega-3-acid ethyl esters: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ) for BDP patients receiving CBT. Patients with BDP will be randomly allocated to the three arms of the study: 1- CBT+placebo, 2- CBT+Omacor 1680 mg/d, 3- CBT+Omacor 3360 mg/d. Follow up will last for 12 weeks. Assessment of affective symptoms, impulsivity and aggressivity will be carried out at baseline and at 2, 4, 6, 8, 10 and 12 weeks.

Condition Intervention Phase
Borderline Personality Disorder. Drug: Omacor® Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial.

Resource links provided by NLM:

Further study details as provided by Hospital Universitari Vall d'Hebron Research Institute:

Primary Outcome Measures:
  • Affective symptoms measured with the Hamilton Depression Scale (Ham-D) and the Young Mania Rating Scale (YMRS). [ Time Frame: weeks: 0, 2, 4, 6, 8, 10, 12 ]
  • Impulsivity and aggressivity measured with the Time Paradigsm and the the Point Subtraction Aggression Paradigm. [ Time Frame: 0, 6, 12 ]

Secondary Outcome Measures:
  • Impulsivity assessed by means of Barratt Impulsivity Scale-11 (BIS-11) [ Time Frame: Weeks 0, 2, 4, 6, 8, 10, 12 ]
  • Anger assessed by means of the State-Trait Anger Expression Inventory 2 (STAXI-2) [ Time Frame: Weeks 0, 2, 4, 6, 8, 10, 12 ]
  • anxiety assessed by means of the State-Trait Anxiety Inventory (STAI-E) [ Time Frame: weeks: 0, 6, 12 ]
  • Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Weeks: 0, 6, 12 ]
  • Global Activity Scale (EEAG) [ Time Frame: Weeks: 0, 6, 12 ]
  • Consumption of addictive substances with urine and breath drug testings and self-reports. [ Time Frame: Every week throghout the study ]
  • Social Adaptation Self-evaluation Scale (SASS) [ Time Frame: Weeks: 0, 6, 12 ]
  • Number of suicidal and parasuicidal episodes. [ Time Frame: Every week throughout the study ]
  • Number of visits to a psychiatric emergency service. [ Time Frame: Every week throughout the study ]
  • Plasmatic BDNF. [ Time Frame: Weeks 0, 12 ]
  • Adverse events. [ Time Frame: Every week throughout the study ]
  • Clinical impression assessed by means ICG [ Time Frame: weeks: 0, 2, 4, 6, 8, 10, 12 ]
  • Adverse events [ Time Frame: at each study visit ]
  • immediate memory assessed by means of the Immediate Memory Task [ Time Frame: Weeks 0, 6, 12 ]
  • Impulsivity assessed by means the two choice delayed reward test [ Time Frame: weeks: 0, 6, 12 ]

Estimated Enrollment: 102
Study Start Date: February 2009
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
subjects with BPD receiving Omacor 1.680 mg/d
Drug: Omacor®
arm 1: Omacor 1680 Arm 2: Omacor 3360
Experimental: 2
BPD patients randomized to Omacor 3.360 mg/d
Drug: Omacor®
arm 1: Omacor 1680 Arm 2: Omacor 3360
Placebo Comparator: 3
patients with BPD randomized to Placebo
Drug: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Meet DSM-IV criteria for BPD assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).
  2. Clinical Global Impression of Severity for BDP > 3.
  3. Age between 18 and 65 years.
  4. Be able to give informed consent for participation.
  5. Place of residency compatible with the assistance to the center.
  6. If woman, use of effective contraception.

Exclusion Criteria:

  1. Have a serious medical illness.
  2. History of omacor® allergy.
  3. Current diagnostic unipolar depression, bipolar disorder type I, Obsessive-Compulsive Disorder, schizophrenia and other psychotic disorders.
  4. DIB-R > 8.
  5. Suicidal thinking that requires hospital admission.
  6. Meet DSM-IV criteria for alcohol, benzodiazepine, opioid or psychostimulant dependence in the six months prior to trial entry.
  7. Transaminase elevation within three times the upper limits of normality.
  8. Treatment with stable doses of antidepressants or mood stabilizers for less than six weeks.
  9. Treatment with stable doses of antipsychotics for more than 1 week in the last three months.
  10. Have received electroconvulsive therapy for the six months prior to trial entry.
  11. Have received DBT in the last 12 months prior to trial entry.
  12. Are pregnant or nursing.
  13. Have participated in any other investigational study in the last 6 months prior to trial entry.
  14. Current treatment or expectation to start any treatment with drugs that may interact with the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00437099

Contact: Miquel Casas, Prof 0034 93 489 42 94
Contact: Xavier Castells, MD 0034 93 489 42 94

Hospital Universitari Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Miquel Casas, MD., Prof.    0034 93 489 42 94   
Sub-Investigator: Marc Ferrer, MD         
Sub-Investigator: Laura Alvarez         
Sub-Investigator: Oscar Andion         
Sub-Investigator: Jose L Matali         
Sub-Investigator: Sergi Valero         
Sub-Investigator: Xavier Castells, MD         
Sponsors and Collaborators
Hospital Universitari Vall d'Hebron Research Institute
Principal Investigator: Miquel Casas, MD., Prof. Hospital Universitari Vall d'Hebron Barcelona, Catalonia, Spain
  More Information

Responsible Party: Miguel Casas Brugué, s Identifier: NCT00437099     History of Changes
Other Study ID Numbers: TLP-OMEGA 3
Study First Received: February 16, 2007
Last Updated: May 26, 2010

Additional relevant MeSH terms:
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders processed this record on September 21, 2017